| 000 | 01574cam a2200349 a 4500 | ||
|---|---|---|---|
| 003 | EG-GiCUC | ||
| 005 | 20250223030906.0 | ||
| 008 | 131120s2013 ua dh f m 000 0 eng d | ||
| 040 |
_aEG-GiCUC _beng _cEG-GiCUC |
||
| 041 | 0 | _aeng | |
| 049 | _aDeposite | ||
| 097 | _aPh.D | ||
| 099 | _aCai01.19.03.Ph.D.2013.No.E | ||
| 100 | 0 | _aNoha Hassan Radwan | |
| 245 | 1 | 0 |
_aEvaluation of glypican3 in in patients with hepatocellular carcinoma / _cNoha Hassan Radwan ; Supervised Nevine Mostafa Elhefnawi , Heba Mohammed Elzawahry , Ghada Mossallam |
| 246 | 1 | 5 | _aفى حالات اورام الكبد السرطانية Glypican3 تقييم |
| 260 |
_aCairo : _bNoha Hassan Radwan , _c2013 |
||
| 300 |
_a208 P. : _bchats , facsimiles ; _c25cm |
||
| 502 | _aThesis (Ph.D.) - Cairo University - National Cancer Institute - Department of Clinical Pathology | ||
| 520 | _aHepatocellular carcinoma (HCC) is a major health problem. it has been increasing in Egypt with doubling in the incidence rale in the past 10 years. it represents the most common primary malignant tumor of the liver and is one of the major causes of death. early diagnosis of HCC is critical for a good prognosis. | ||
| 530 | _aIssued also as CD | ||
| 653 | 4 | _aELISA | |
| 653 | 4 | _aGlypican-3 | |
| 653 | 4 | _aPCR | |
| 700 | 0 |
_aGhada Mossallam , _eSupervisor |
|
| 700 | 0 |
_aHeba Mohammed Elzawahry , _eSupervisor |
|
| 700 | 0 |
_aNevine Mostafa Elhefnawi , _eSupervisor |
|
| 856 | _uhttp://172.23.153.220/th.pdf | ||
| 905 |
_aAml _eCataloger |
||
| 905 |
_aNazla _eRevisor |
||
| 942 |
_2ddc _cTH |
||
| 999 |
_c44131 _d44131 |
||